APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
| Application |
Recommended Dilution |
| 0.2-2.5 ug/ml |
| 2-10 ug/ml |
Not tested in other applications.
Calculated MW
Positive Control
Jurkat
PROPERTIES
Form
Liquid
Buffer
PBS, 2% Sucrose
Preservative
0.09% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
0.5-1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
A synthetic peptide corresponding to a C-terminal region of Human FIP1L1
Purification
Affinity Purified
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
factor interacting with PAPOLA and CPSF1 , FIP1 , Rhe , hFip1
Cellular Localization
Nucleus
Background
This gene encodes a subunit of the CPSF (cleavage and polyadenylation specificity factor) complex that polyadenylates the 3' end of mRNA precursors. This gene, the homolog of yeast Fip1 (factor interacting with PAP), binds to U-rich sequences of pre-mRNA and stimulates poly(A) polymerase activity. Its N-terminus contains a PAP-binding site and its C-terminus an RNA-binding domain. An interstitial chromosomal deletion on 4q12 creates an in-frame fusion of human genes FIP1L1 and PDGFRA (platelet-derived growth factor receptor, alpha). The FIP1L1-PDGFRA fusion gene encodes a constitutively activated tyrosine kinase that joins the first 233 amino acids of FIP1L1 to the last 523 amino acids of PDGFRA. This gene fusion and chromosomal deletion is the cause of some forms of idiopathic hypereosinophilic syndrome (HES). This syndrome, recently reclassified as chronic eosinophilic leukemia (CEL), is responsive to treatment with tyrosine kinase inhibitors. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008]
Database
DATA IMAGES
|
GTX47245 WB Image
WB analysis of Jurkat cells using GTX47245 FIP1L1 antibody at 0.2-1μg/ml.
|
|
|
GTX47245 IHC-P Image
IHC-P analysis of human brain tissue using GTX47245 FIP1L1 antibody at 4.0-8.0μg/ml.
|
REFERENCE
There are currently no references for FIP1L1 antibody, C-term (GTX47245). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for FIP1L1 antibody, C-term (GTX47245). Be the first to share your experience with this product.
